Preclinical CRO Market Size, Growth & Demand

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Preclinical CRO Market Size Analysis

Global Preclinical CRO Market Introduction
By Service
1. Introduction
  1. Service By Value
2. Bioanalysis and DMPK studies
  1. By Value
  2. In vitro ADME
    1. In vitro ADME By Value
  3. In-vivo PK
    1. In-vivo PK By Value
3. Toxicology Testing
  1. By Value
  2. GLP
    1. GLP By Value
  3. Non-GLP
    1. Non-GLP By Value
4. Compound Management
  1. By Value
  2. Process R&D
    1. Process R&D By Value
  3. Custom Synthesis
    1. Custom Synthesis By Value
  4. Others
    1. Others By Value
5. Chemistry
  1. By Value
  2. Medicinal Chemistry
    1. Medicinal Chemistry By Value
  3. Computation Chemistry
    1. Computation Chemistry By Value
6. Safety Pharmacology
  1. By Value
7. Others
  1. By Value
By Model
1. Introduction
  1. Model By Value
2. Patient-Derived Organoid (PDO) Model
  1. By Value
3. Patient-Derived Xenograft Model
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Oncology
  1. By Value
3. Neurology
  1. By Value
4. Cardiology
  1. By Value
5. Infectious Diseases
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biotechnological Companies
  1. By Value
3. Government and Academic Institutes
  1. By Value
4. Medical Device Companies
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Bioanalysis and DMPK studies
  1. By Value
  2. In vitro ADME
    1. In vitro ADME By Value
  3. In-vivo PK
    1. In-vivo PK By Value
3. Toxicology Testing
  1. By Value
  2. GLP
    1. GLP By Value
  3. Non-GLP
    1. Non-GLP By Value
4. Compound Management
  1. By Value
  2. Process R&D
    1. Process R&D By Value
  3. Custom Synthesis
    1. Custom Synthesis By Value
  4. Others
    1. Others By Value
5. Chemistry
  1. By Value
  2. Medicinal Chemistry
    1. Medicinal Chemistry By Value
  3. Computation Chemistry
    1. Computation Chemistry By Value
6. Safety Pharmacology
  1. By Value
7. Others
  1. By Value
By Model
1. Introduction
  1. Model By Value
2. Patient-Derived Organoid (PDO) Model
  1. By Value
3. Patient-Derived Xenograft Model
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Oncology
  1. By Value
3. Neurology
  1. By Value
4. Cardiology
  1. By Value
5. Infectious Diseases
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biotechnological Companies
  1. By Value
3. Government and Academic Institutes
  1. By Value
4. Medical Device Companies
  1. By Value
5. Others
  1. By Value
U.S.
1. By Service
  1. Introduction
    1. Service By Value
  2. Bioanalysis and DMPK studies
    1. By Value
    2. In vitro ADME
      1. In vitro ADME By Value
    3. In-vivo PK
      1. In-vivo PK By Value
  3. Toxicology Testing
    1. By Value
    2. GLP
      1. GLP By Value
    3. Non-GLP
      1. Non-GLP By Value
  4. Compound Management
    1. By Value
    2. Process R&D
      1. Process R&D By Value
    3. Custom Synthesis
      1. Custom Synthesis By Value
    4. Others
      1. Others By Value
  5. Chemistry
    1. By Value
    2. Medicinal Chemistry
      1. Medicinal Chemistry By Value
    3. Computation Chemistry
      1. Computation Chemistry By Value
  6. Safety Pharmacology
    1. By Value
  7. Others
    1. By Value
2. By Model
  1. Introduction
    1. Model By Value
  2. Patient-Derived Organoid (PDO) Model
    1. By Value
  3. Patient-Derived Xenograft Model
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Oncology
    1. By Value
  3. Neurology
    1. By Value
  4. Cardiology
    1. By Value
  5. Infectious Diseases
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biotechnological Companies
    1. By Value
  3. Government and Academic Institutes
    1. By Value
  4. Medical Device Companies
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Bioanalysis and DMPK studies
  1. By Value
  2. In vitro ADME
    1. In vitro ADME By Value
  3. In-vivo PK
    1. In-vivo PK By Value
3. Toxicology Testing
  1. By Value
  2. GLP
    1. GLP By Value
  3. Non-GLP
    1. Non-GLP By Value
4. Compound Management
  1. By Value
  2. Process R&D
    1. Process R&D By Value
  3. Custom Synthesis
    1. Custom Synthesis By Value
  4. Others
    1. Others By Value
5. Chemistry
  1. By Value
  2. Medicinal Chemistry
    1. Medicinal Chemistry By Value
  3. Computation Chemistry
    1. Computation Chemistry By Value
6. Safety Pharmacology
  1. By Value
7. Others
  1. By Value
By Model
1. Introduction
  1. Model By Value
2. Patient-Derived Organoid (PDO) Model
  1. By Value
3. Patient-Derived Xenograft Model
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Oncology
  1. By Value
3. Neurology
  1. By Value
4. Cardiology
  1. By Value
5. Infectious Diseases
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biotechnological Companies
  1. By Value
3. Government and Academic Institutes
  1. By Value
4. Medical Device Companies
  1. By Value
5. Others
  1. By Value
U.K.
1. By Service
  1. Introduction
    1. Service By Value
  2. Bioanalysis and DMPK studies
    1. By Value
    2. In vitro ADME
      1. In vitro ADME By Value
    3. In-vivo PK
      1. In-vivo PK By Value
  3. Toxicology Testing
    1. By Value
    2. GLP
      1. GLP By Value
    3. Non-GLP
      1. Non-GLP By Value
  4. Compound Management
    1. By Value
    2. Process R&D
      1. Process R&D By Value
    3. Custom Synthesis
      1. Custom Synthesis By Value
    4. Others
      1. Others By Value
  5. Chemistry
    1. By Value
    2. Medicinal Chemistry
      1. Medicinal Chemistry By Value
    3. Computation Chemistry
      1. Computation Chemistry By Value
  6. Safety Pharmacology
    1. By Value
  7. Others
    1. By Value
2. By Model
  1. Introduction
    1. Model By Value
  2. Patient-Derived Organoid (PDO) Model
    1. By Value
  3. Patient-Derived Xenograft Model
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Oncology
    1. By Value
  3. Neurology
    1. By Value
  4. Cardiology
    1. By Value
  5. Infectious Diseases
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biotechnological Companies
    1. By Value
  3. Government and Academic Institutes
    1. By Value
  4. Medical Device Companies
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Bioanalysis and DMPK studies
  1. By Value
  2. In vitro ADME
    1. In vitro ADME By Value
  3. In-vivo PK
    1. In-vivo PK By Value
3. Toxicology Testing
  1. By Value
  2. GLP
    1. GLP By Value
  3. Non-GLP
    1. Non-GLP By Value
4. Compound Management
  1. By Value
  2. Process R&D
    1. Process R&D By Value
  3. Custom Synthesis
    1. Custom Synthesis By Value
  4. Others
    1. Others By Value
5. Chemistry
  1. By Value
  2. Medicinal Chemistry
    1. Medicinal Chemistry By Value
  3. Computation Chemistry
    1. Computation Chemistry By Value
6. Safety Pharmacology
  1. By Value
7. Others
  1. By Value
By Model
1. Introduction
  1. Model By Value
2. Patient-Derived Organoid (PDO) Model
  1. By Value
3. Patient-Derived Xenograft Model
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Oncology
  1. By Value
3. Neurology
  1. By Value
4. Cardiology
  1. By Value
5. Infectious Diseases
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biotechnological Companies
  1. By Value
3. Government and Academic Institutes
  1. By Value
4. Medical Device Companies
  1. By Value
5. Others
  1. By Value
China
1. By Service
  1. Introduction
    1. Service By Value
  2. Bioanalysis and DMPK studies
    1. By Value
    2. In vitro ADME
      1. In vitro ADME By Value
    3. In-vivo PK
      1. In-vivo PK By Value
  3. Toxicology Testing
    1. By Value
    2. GLP
      1. GLP By Value
    3. Non-GLP
      1. Non-GLP By Value
  4. Compound Management
    1. By Value
    2. Process R&D
      1. Process R&D By Value
    3. Custom Synthesis
      1. Custom Synthesis By Value
    4. Others
      1. Others By Value
  5. Chemistry
    1. By Value
    2. Medicinal Chemistry
      1. Medicinal Chemistry By Value
    3. Computation Chemistry
      1. Computation Chemistry By Value
  6. Safety Pharmacology
    1. By Value
  7. Others
    1. By Value
2. By Model
  1. Introduction
    1. Model By Value
  2. Patient-Derived Organoid (PDO) Model
    1. By Value
  3. Patient-Derived Xenograft Model
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Oncology
    1. By Value
  3. Neurology
    1. By Value
  4. Cardiology
    1. By Value
  5. Infectious Diseases
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biotechnological Companies
    1. By Value
  3. Government and Academic Institutes
    1. By Value
  4. Medical Device Companies
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Bioanalysis and DMPK studies
  1. By Value
  2. In vitro ADME
    1. In vitro ADME By Value
  3. In-vivo PK
    1. In-vivo PK By Value
3. Toxicology Testing
  1. By Value
  2. GLP
    1. GLP By Value
  3. Non-GLP
    1. Non-GLP By Value
4. Compound Management
  1. By Value
  2. Process R&D
    1. Process R&D By Value
  3. Custom Synthesis
    1. Custom Synthesis By Value
  4. Others
    1. Others By Value
5. Chemistry
  1. By Value
  2. Medicinal Chemistry
    1. Medicinal Chemistry By Value
  3. Computation Chemistry
    1. Computation Chemistry By Value
6. Safety Pharmacology
  1. By Value
7. Others
  1. By Value
By Model
1. Introduction
  1. Model By Value
2. Patient-Derived Organoid (PDO) Model
  1. By Value
3. Patient-Derived Xenograft Model
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Oncology
  1. By Value
3. Neurology
  1. By Value
4. Cardiology
  1. By Value
5. Infectious Diseases
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biotechnological Companies
  1. By Value
3. Government and Academic Institutes
  1. By Value
4. Medical Device Companies
  1. By Value
5. Others
  1. By Value
UAE
1. By Service
  1. Introduction
    1. Service By Value
  2. Bioanalysis and DMPK studies
    1. By Value
    2. In vitro ADME
      1. In vitro ADME By Value
    3. In-vivo PK
      1. In-vivo PK By Value
  3. Toxicology Testing
    1. By Value
    2. GLP
      1. GLP By Value
    3. Non-GLP
      1. Non-GLP By Value
  4. Compound Management
    1. By Value
    2. Process R&D
      1. Process R&D By Value
    3. Custom Synthesis
      1. Custom Synthesis By Value
    4. Others
      1. Others By Value
  5. Chemistry
    1. By Value
    2. Medicinal Chemistry
      1. Medicinal Chemistry By Value
    3. Computation Chemistry
      1. Computation Chemistry By Value
  6. Safety Pharmacology
    1. By Value
  7. Others
    1. By Value
2. By Model
  1. Introduction
    1. Model By Value
  2. Patient-Derived Organoid (PDO) Model
    1. By Value
  3. Patient-Derived Xenograft Model
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Oncology
    1. By Value
  3. Neurology
    1. By Value
  4. Cardiology
    1. By Value
  5. Infectious Diseases
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biotechnological Companies
    1. By Value
  3. Government and Academic Institutes
    1. By Value
  4. Medical Device Companies
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Bioanalysis and DMPK studies
  1. By Value
  2. In vitro ADME
    1. In vitro ADME By Value
  3. In-vivo PK
    1. In-vivo PK By Value
3. Toxicology Testing
  1. By Value
  2. GLP
    1. GLP By Value
  3. Non-GLP
    1. Non-GLP By Value
4. Compound Management
  1. By Value
  2. Process R&D
    1. Process R&D By Value
  3. Custom Synthesis
    1. Custom Synthesis By Value
  4. Others
    1. Others By Value
5. Chemistry
  1. By Value
  2. Medicinal Chemistry
    1. Medicinal Chemistry By Value
  3. Computation Chemistry
    1. Computation Chemistry By Value
6. Safety Pharmacology
  1. By Value
7. Others
  1. By Value
By Model
1. Introduction
  1. Model By Value
2. Patient-Derived Organoid (PDO) Model
  1. By Value
3. Patient-Derived Xenograft Model
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Oncology
  1. By Value
3. Neurology
  1. By Value
4. Cardiology
  1. By Value
5. Infectious Diseases
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biotechnological Companies
  1. By Value
3. Government and Academic Institutes
  1. By Value
4. Medical Device Companies
  1. By Value
5. Others
  1. By Value
Brazil
1. By Service
  1. Introduction
    1. Service By Value
  2. Bioanalysis and DMPK studies
    1. By Value
    2. In vitro ADME
      1. In vitro ADME By Value
    3. In-vivo PK
      1. In-vivo PK By Value
  3. Toxicology Testing
    1. By Value
    2. GLP
      1. GLP By Value
    3. Non-GLP
      1. Non-GLP By Value
  4. Compound Management
    1. By Value
    2. Process R&D
      1. Process R&D By Value
    3. Custom Synthesis
      1. Custom Synthesis By Value
    4. Others
      1. Others By Value
  5. Chemistry
    1. By Value
    2. Medicinal Chemistry
      1. Medicinal Chemistry By Value
    3. Computation Chemistry
      1. Computation Chemistry By Value
  6. Safety Pharmacology
    1. By Value
  7. Others
    1. By Value
2. By Model
  1. Introduction
    1. Model By Value
  2. Patient-Derived Organoid (PDO) Model
    1. By Value
  3. Patient-Derived Xenograft Model
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Oncology
    1. By Value
  3. Neurology
    1. By Value
  4. Cardiology
    1. By Value
  5. Infectious Diseases
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biotechnological Companies
    1. By Value
  3. Government and Academic Institutes
    1. By Value
  4. Medical Device Companies
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Preclinical CRO Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Charles River Laboratories International, Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Covance Inc.
ICON plc
Medpace, Inc.
WuXi AppTec
Envigo
PRA Health Sciences
Syngene International Limited
Eurofins Scientific
Parexel International Corporation
SGS SA
MPI Research
Crown Bioscience, Inc.
Toxikon Corporation
Pharmaron

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment